Helomics
Predictive Oncology is dedicated to advancing drug discovery and development through artificial intelligence, machine learning, and innovative biobank resources. Their mission is to improve the success rate of clinical trials, accelerate cancer therapies, and support biopharma partners with proprietary solutions and research platforms. They utilize 3D tumor models, spheroids, and organoids to recreate the complex human organ microenvironment, supporting long-term survival of tumor and immune components, and exhibit high correlation with clinical responses. The company also focuses on biomarker discovery, drug repurposing, and increasing the probability of technical success in drug development. Their vision is to transform oncology research and improve patient outcomes.
Industries
Nr. of Employees
medium (51-250)
Products
Active ML experimental design platform
Platform that integrates active‑learning machine learning, a large patient‑derived tumor biobank, and iterative wet‑lab testing to produce prioritized compound–tumor pairing predictions and guide experimental campaigns.
3D organoid assay kits and reagents
Pre‑packaged organ‑specific 3D culture kits built around patient‑derived cells and organ‑specific extracellular matrix formulations for use in drug testing workflows; compatible with standard analytical readouts and automated workflows.
AI‑driven formulation screening platform
Computational and experimental service that evaluates large excipient combination spaces to identify candidate formulations for biologics using minimal protein quantities.
Endotoxin detection and removal kits/services
Analytical kits and removal workflows for detection of protein‑bound endotoxin and for removing endotoxin from biologic solutions across diverse chemistries.
Active ML experimental design platform
Platform that integrates active‑learning machine learning, a large patient‑derived tumor biobank, and iterative wet‑lab testing to produce prioritized compound–tumor pairing predictions and guide experimental campaigns.
3D organoid assay kits and reagents
Pre‑packaged organ‑specific 3D culture kits built around patient‑derived cells and organ‑specific extracellular matrix formulations for use in drug testing workflows; compatible with standard analytical readouts and automated workflows.
AI‑driven formulation screening platform
Computational and experimental service that evaluates large excipient combination spaces to identify candidate formulations for biologics using minimal protein quantities.
Endotoxin detection and removal kits/services
Analytical kits and removal workflows for detection of protein‑bound endotoxin and for removing endotoxin from biologic solutions across diverse chemistries.
Services
Collaborative pilot campaigns offering academic investigators access to an active‑learning ML platform and patient‑derived biobank for early‑stage candidate evaluation, with data and IP protections and options for no‑cost participation for eligible partners.
Clinical laboratory services performing live‑cell tumor response assays alongside genomic biomarker profiling to support personalized therapy selection and clinical research activities in a certified lab environment.
Contract testing using multi‑cellular 3D tumor and organ‑specific models, including co‑culture formats with stroma and immune components; services include custom model creation and on‑site assay execution with support for automated, high‑throughput workflows and multiple analytical readouts.
Integrated specimen management, histopathology, and diagnostic research support for pharmaceutical and academic studies, including sample storage, tissue processing, and linked pathology reporting.
Contract formulation development using computational screening of excipient combinations and empirical testing to identify stable, soluble biologic formulations using small protein quantities.
Analytical testing for protein‑bound endotoxin and contract removal workflows capable of addressing diverse endotoxin chemistries in biologic solutions.
Collaborative pilot campaigns offering academic investigators access to an active‑learning ML platform and patient‑derived biobank for early‑stage candidate evaluation, with data and IP protections and options for no‑cost participation for eligible partners.
Clinical laboratory services performing live‑cell tumor response assays alongside genomic biomarker profiling to support personalized therapy selection and clinical research activities in a certified lab environment.
Contract testing using multi‑cellular 3D tumor and organ‑specific models, including co‑culture formats with stroma and immune components; services include custom model creation and on‑site assay execution with support for automated, high‑throughput workflows and multiple analytical readouts.
Integrated specimen management, histopathology, and diagnostic research support for pharmaceutical and academic studies, including sample storage, tissue processing, and linked pathology reporting.
Contract formulation development using computational screening of excipient combinations and empirical testing to identify stable, soluble biologic formulations using small protein quantities.
Analytical testing for protein‑bound endotoxin and contract removal workflows capable of addressing diverse endotoxin chemistries in biologic solutions.
Expertise Areas
- Active‑learning machine‑learning for experimental design
- Predictive modeling of tumor–drug response using biobank and genomic data
- Patient‑derived tumor biobank management and testing
- 3D tumor and organoid model development and scale‑up
Key Technologies
- Active‑learning machine learning
- Machine learning for biological data
- Large dissociated tumor cell biobank
- 3D organoid and spheroid culture